In addition to issues relating to the reliability of compounded products themselves, appropriate clinical studies on pharmacokinetics are lacking. In contrast to commercial pharmaceutical manufacturing, which is regulated by the FDA, compounded medications are regulated by state laws and, therefore, vary significantly from one region to another.405 While testosterone gels and creams are the most commonly used forms of compounded testosterone therapies and are routinely less expensive than branded forms of testosterone, these preparations by individual pharmacies occur without direct FDA oversight and approval. + FDA approved for use in males with hypogonadotropic hypogonadism and pediatric patients with cryptorchidism. Despite these effects, neither treatment led to significant changes in semen parameters.403 Taylor et al. reported that clomiphene citrate has outstanding biochemical and clinical efficacy, with increases in serum testosterone similar to those for testosterone gel.400 Additionally, these investigators found that clomiphene has a favorable side effect profile and is less expensive than testosterone gel. SERMs are oral agents that block E2 feedback resulting in increased LH secretion. However, despite these limitations, several studies provide important insights into the impact of SERMs, AIs, and hCG on spermatogenesis. Prospective, observational studies show that visceral adiposity, smoking and the metabolic syndrome predict the development of low testosterone levels 33,34. Numerous long-term studies, and various reviews and meta-analyses, have provided evidence to support the association between testosterone deficiency (TD) and increased cardiovascular (CV) and all-cause mortality 20,21,22,23,24,25, although evidence for a pathogenic link is lacking 26,27. However, after testosterone administration, there was an improvement in basal and post-load levels of insulin and blood glucose. However, as patients with KS are, per se, more prone to the development of metabolic syndrome independently of their testosterone levels, it is highly likely that in our patient both syndromes might have influenced each other in a positive feedback manner, leading to the current medical condition. The use of testosterone as replacement therapy in patients with hypogonadism induces metabolic changes that lead to higher insulin sensitivity (decreased fat mass and increased lean mass, less insulin resistance and higher insulin secretion) 1, 2. The testosterone preparation we used in our study was a 2% testosterone gel applied daily, in the morning, on the skin of the abdomen; this application caused a peak of testosterone levels between 2 and 4 h after administration and maintained testosterone levels above baseline for approximately 12 h . In a 2011 meta-analysis Corona et al's study , found baseline TT was 2.08 nmol/L (95% CI, 3.57 to 0.59) lower in men who developed incident T2DM compared with those who did not. The evidence suggests that low testosterone leads to new onset T2DM and contributes to worsening comorbidities 8,9,10. On the contrary, evidence suggests that men classified as ‘functional HG’ form the majority of patients showing benefit from clinical trials . In men, there is now strong evidence linking low testosterone to obesity, T2DM and components of the metabolic syndrome . Other risk factors are lack of exercise, family history, and gestational diabetes. Meta-analyses of RCT, rather than providing clarification, have further confused the issue by including under-powered studies of inadequate duration, multiple regimes, some discontinued, and inbuilt bias in terms of studies included or excluded from analysis. Post-maximum testosterone concentrations decreased with an estimated half-life of approximately 53 days. An increase in serum testosterone concentrations above basal values may be measured one day after administration. Following intramuscular injection, it is gradually released from the depot and almost completely cleaved by serum esterases into testosterone and undecanoic acid. In the IM testosterone group, there were no new cases of gynecomastia, and one patient with pre-existing gynecomastia had gynecomastia resolution.181 For men who develop gynecomastia/breast symptoms while on treatment (e.g., breast pain, breast tenderness, nipple tenderness), a period of monitoring based on clinical judgment should be considered, as breast symptoms sometimes abate. An evaluation for a prolactinoma in such patients is imperative because these benign tumors can be effectively managed using medications, such as bromocriptine or carbergoline. However, the literature at this time fails to define the LH level below which such adjunctive testing is warranted. The validated instruments include ADAM, Quantitative ADAM, Aging Male Survey (AMS), MMAS, and the ANDROTEST.10, 166, 167 Specificities and sensitivities vary greatly amongst these tests making them ill-suited for screening or for use as a surrogate for testosterone laboratory testing. Depending upon the radiation dose, delivery modality, and underlying tumor type, LH deficiency rates in patients whose pituitary gland has been exposed to radiation is 10-96%.160 Radiation to the brain that exposes the pituitary gland can also result in pituitary dysfunction and low testosterone.
